Aug 04, 2016 - With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Aug 04, 2016 - With Repros being a development-stage company, investors will remain focused on the company's pipeline and cash burn.
Aug 04, 2016 - With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
Jul 29, 2016 - ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
Jul 26, 2016 - Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
Jul 21, 2016 - The combination of Lilly's Zacks Rank #3 and +1.18% ESP makes us very confident in looking for a positive earnings beat on Jul 26.
Sep 17, 2015 - Incyte Corporation (NASDAQ:INCY) Morgan Stanley 2015 Global Healthcare Conference Call September 17, 2015 12:20 PM ET Executives Herve Hoppenot – President and Chief Executive Officer Analysts Andrew
Sep 11, 2015 - Aduro (ADRO) signed a clinical study agreement with Incyte (INCY) to evaluate CRS-207, in combination with Incyte's epacadostat, in patients with ovarian cancer.
Sep 04, 2015 - The positive earnings estimate revisions suggest that analysts are becoming more optimistic on Incyte Corporation’s earnings for the coming quarter and year